Winrevair (sotatercept) is the first activin signalling inhibitor therapy approved to treat pulmonary arterial hypertension (PAH) and the first new medicine approved for the treatment of PAH in nearly a decade.
Access our deep dive into this approval - in a useful, downloadable PDF format.
Read Now
Sign up to our monthly newsletter. Our newsletter gives you the latest European and UK regulatory intelligence. We bring you new and interesting approvals; fast-to-market applications, orphan designations; paediatric applications and therapy area-specific news.
You can unsubscribe at any time from the link in the newsletter footer. Read our Privacy Policy here.